Ads
related to: editas medicine stock price target
Search results
Results From The WOW.Com Content Network
The average of price targets set by Wall Street analysts indicates a potential upside of 64.9% in Editas (EDIT). While the effectiveness of this highly sought-after metric is questionable, the ...
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. [ 2 ] [ 3 ] Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado .
Market forces rained on the parade of Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders today, when the analysts...
Here's the story behind the biotech stock that could be the best way to profit from the discovery of the century: CRISPR-Cas9 gene editing.
Today is shaping up negative for Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders, with the analysts delivering a...
Juno Therapeutics Inc. was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop ...
On Monday, shares of Editas Medicine (NASDAQ: EDIT) saw unusual options activity. After the option alert, the stock price moved up to $31.43. * Sentiment: BEARISH * Option Type: TRADE * Trade Type ...
James Mullen (CEO) James C. “Jim” Mullen (born ca. 1958) is an American business executive. He is the executive chairman at genome editing company Editas Medicine since 2018, where he also served as CEO between 2021 and 2022. [1][2][3] He was formerly the president and CEO of Biogen Idec until he retired effective June 8, 2010. [4]